Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06745206

Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock

Sponsor: Sichuan Provincial People's Hospital

View on ClinicalTrials.gov

Summary

As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.

Official title: Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock: An Interventional Pilot Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-12

Completion Date

2026-09

Last Updated

2025-07-29

Healthy Volunteers

Conditions

Sepsis-induced Cardiomyopathy the Recovery Phase of Septic Shock

Interventions

DRUG

Lyophilized Recombinant Human Brain Natriuretic Peptide

rh-BNP is reconstituted to a concentration of 10 μg/mL and administered as an initial intravenous bolus of 2 μg/kg over 15 minutes, followed by a continuous infusion at a rate of 0.01 μg/kg/min. Patients should receive at least the first 500μg dose infusion, with a recommended duration of 72 hours. The specific timing of discontinuation will be determined by the attending physician. Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.

Inclusion criteria: 1. Age \>18 years. 2. Septic shock in recovery phase with decreasing vasopressor requirements, which is defined as: 1. Fulfilling the Sepsis-3 definition of septic shock at initial stage. 2. Hemodynamic stability achieved after adequate initial resuscitation and individualized hemodynamic optimization. 3. Controlled infection source with 48-hour trend of improving temperature, white blood cell count, and procalcitonin. 4. 48-hour trend of decreasing vasopressor requirements and transition to negative fluid balance. 5. Adequate perfusion with warm extremities, and capillary refill time \<3 seconds. 3. Ongoing pulse index continuous cardiac output (PiCCO) hemodynamic monitoring and sinus rhythm. 4. Volume indicators above the lower limit of normal range, with global end-diastolic volume index (GEDI) \>680 mL/m2 and central venous pressure (CVP) \>8 mmHg. 5. Signs of cardiac dysfunction: BNP\>200\[10\] or NT-proBNP \>900 pg/ml\[6\] or reduced ejection fraction (LVEF) \< 50%. 6. No bolus dose of diuretics had been administered in the previous 6 hours. 7. Informed consent obtained from patient/legal representative. Exclusion Criteria: 1. Pregnancy or lactation. 2. Arrhythmia. 3. Advanced renal dysfunction (Acute Kidney Injury \[AKI\] stage 3 or Chronic Kidney Disease \[CKD\] stage 3b or higher) based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria. 4. Inadequate ultrasound window preventing acquisition of diagnostic-quality images. 5. Trauma or neurological diseases (including intracerebral hemorrhage and cerebral infarction). 6. Pre-existing severe heart failure (New York Heart Association \[NYHA\] class III-IV) or acute myocardial infarction within the past 30 days. 7. Concurrent enrollment in interventional trials that could confound study outcomes. Criteria for withdrawing from the study: 1. Withdrawal of the informed consent. 2. Severe hemodynamic deterioration necessitating the discontinuation of all vasodilatory medications. 3. Treating clinician's decision.